IP Library Granted Patent US 8,933,022
Granted Patent B2
US 8,933,022 · App. 13/409,960 · Granted Jan 13, 2015

Methods and compositions for the treatment and prevention Hypoglycemia and related disorders

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,933,022
App. No.
13/409,960
Granted
Jan 13, 2015
Kind
B2
Abstract

A composition comprising chromium and insulin and/or a chromium-insulin complex, its method of preparation, and its use in the prevention and treatment of hypoglycemia and hypoglycemia-related conditions. This composition can be administered in numerous ways, including parenterally, intranasally, and orally. The composition stabilizes serum glucose levels and has a synergistic effect compared to chromium and insulin administered separately.

Claims (12)

1. A composition consisting essentially of a chromium-insulin complex that is insoluble in deionized water at room temperature, wherein the chromium-insulin complex comprises between 4 and 6 chromium ions and six molecules of insulin, and wherein the chromium-insulin complex is formulated for administration to a subject.

2. The composition of claim 1 , wherein the composition is formulated for injection into a subject.

3. The composition of claim 1 , wherein the amount of chromium-insulin complex is effective to reduce weight gain in a subject having type 2 diabetes.

4. The composition of claim 1 , wherein the amount of chromium-insulin complex is effective to reduce weight loss in a subject having type 1 diabetes.

5. The composition of claim 1 , wherein the chromium-insulin complex has a molecular weight between 5 kDa and 50 kDa.

6. The composition of claim 1 , wherein the chromium-insulin complex has a molecular weight of about 33 kDa.

7. The composition of claim 1 , wherein the composition comprises between 5 micrograms and 2,000 micrograms of chromium.

8. The composition of claim 1 , wherein composition comprises between 1 unit and 500 units of insulin.

9. The composition of claim 1 , wherein the chromium-insulin complex is suspended in a solution.

10. The composition of claim 1 , further comprising a nutritionally acceptable carrier.

11. The composition of claim 1 , wherein the chromium-insulin complex is in an aqueous solution.

12. A composition consisting essentially of a therapeutically effective amount of a purified chromium-insulin complex that is insoluble in deionized water at room temperature, wherein the chromium-insulin complex comprises between 4 and 6 chromium ions and six molecules of insulin, and wherein the chromium-insulin is formulated for administration to a subject.

Assignments (3)
SECURITY INTEREST Recorded Nov 9, 2021
From: NUTRITION 21, LLC
To: CAPITAL ONE, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 058060/0535 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2021
From: JDS THERAPEUTICS, LLC
To: NUTRITION 21, LLC
Reel/Frame 056933/0653 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2012
From: KOMOROWSKI, JAMES R.
To: JDS THERAPEUTICS, LLC
Reel/Frame 028190/0050 →